New: March 21, 2023. The NIH sent a response to the Xtandi petition, rejecting the request to use the governments’ rights to lower the price of the prostate cancer treatment. New: March 23, 2023. The petitioners filed an appeal to… Continue Reading
On Wednesday January 12, 2022, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding a prospective exclusive, sublicensable license to the University of Louisville Research Foundation (ULRF), for “Griffithsin Compositions for Treatment and Prevention of… Continue Reading
(Update: On December 15, 2021 KEI hosted a press briefing regarding the Xtandi march-in request. Video and details available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) On November 18, 2021, Robert Sachs and Clare Love submitted a petition to the Secretary of Health and Human… Continue Reading
November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading
(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
(For more resources, please see our page on molnupiravir.) Molnupiravir, the oral pill that is showing promising results as a potential treatment for covid-19, was invented at Emory University with U.S. government funds. After more than six years of non-clinical… Continue Reading
On September 27, 2021, Knowledge Ecology International (KEI) submitted the following comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent License: Chimeric Live-Attenuated Vaccine for West Nile Virus (WNV)” (86 FR 50722). The technology… Continue Reading
Knowledge Ecology International (KEI) filed comments on July 27, 2021 regarding the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene” (86 FR 36563). The inventions are currently co-owned… Continue Reading
On July 27, 2021, Knowledge Ecology International (KEI) commented on the “Prospective Grant of an Exclusive Patent License: RP2 AAV-Based Gene Human Therapy for Ocular Diseases and Disorders Including XLRP” (86 FR 36565). The National Institutes of Health (NIH) intends… Continue Reading
(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading